ONCO · Onconetix, Inc.

Onconetix represents a high-risk turnaround play in oncology diagnostics, pivoting from abandoned ENTADFI BPH treatment to Proclarix, a protein-based blood test addressing PSA test limitations where over 50% of elevated PSA biopsies prove negative. The company's acquisition of Proteomedix in December 2023 secured CE-marked IVDR approval for Europe, with sales efforts yielding expected 2026 revenue growth to offset commercialization scaling costs. U.S. entry hinges entirely on LabCorp's exclusive license, introducing execution risk as Onconetix lacks control over development timelines or marketing success. Manufacturing dependency on single-source third parties further constrains scalability without internal capabilities.

Financially precarious, Onconetix burned $9.7M in operating cash during 2025 against $5.2M year-end cash, posting a $3.1M working capital deficit and $131.2M accumulated losses. Auditors flag substantial going concern doubts, with April 2026 cash at $4.2M insufficient for 12-month operations. Recent Series D/E PIPE financings provided $15.5M but at deeply dilutive terms, with conversion prices reset to ~$0.73 post-reverse split. The ELOC registers 25M shares (68.8% of current float) for up to $25M at 90% VWAP discounts, capping Keystone at 4.99% ownership but enabling rapid dilution if stock weakens further.

The February 2026 Realbotix share exchange looms as transformative or destructive: Seller gains 75-90% fully-diluted ownership contingent on $12.5M+ Net Cash at close, requiring ELOC commitment and Preferred conversions. Failure triggers $500K-$2M fees, potential liquidation, and Board distraction amid recent director resignations (Oakley/Meier) and appointments (Epstein as director). Post-close Board shrinks to 5 members with Realbotix designating 4, signaling near-total control shift.

Investor exposure demands tolerance for 100%+ downside from dilution, execution failures, or deal collapse, balanced against Proclarix's clinical validation in reducing overtreatment. Absent revenue ramp or Realbotix infusion, cash exhaustion forces further dilutive raises or wind-down, with Nasdaq delisting risk if equity conditions falter.